Literature DB >> 6985615

Gonadotropin-estradiol responses to a superactive luteinizing hormone-releasing hormone agonist in women.

R F Casper, K L Sheehan, S S Yen.   

Abstract

After the sc administration of 1, 10, and 50 micrograms of the LRF agonist [D-Trp6,Pro9,NEt]LRF, dose-dependent increments in circulating levels of LH, FSH, and estradiol were observed which were 2- to 3-fold greater in the late than in the early follicular phase. The 10-microgram dose of LFR agonist appears to induce a maximal acute gonadotropin-estradiol response. Both 10- and 50-microgram doses of the agonist elicited gonadotropin increments which were several times greater than that seen during the midcycle surge. The only difference between the two doses was the more sustained action on gonadotropin release of the latter. It is estimated that this superactive LRF agonist is approximately 140 times more potent than the decapeptide LRF. These observations provide information useful in the application of this LRF agonist for clinical studies.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6985615     DOI: 10.1210/jcem-50-1-179

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.

Authors:  C Schmidt-Sarosi; D R Kaplan; P Sarosi; M N Essig; F L Licciardi; M Keltz; M Levitz
Journal:  J Assist Reprod Genet       Date:  1995-03       Impact factor: 3.412

Review 2.  Clinical uses of gonadotropin-releasing hormone analogues.

Authors:  R F Casper
Journal:  CMAJ       Date:  1991-01-15       Impact factor: 8.262

3.  Effect of duration of gonadotropin releasing hormone agonist on the outcome of in vitro fertilization-embryo transfer in a short-acting long regimen.

Authors:  Zhen-Ni Mu; Zhen-Gao Sun; Jing-Yan Song; Hong-Gen Liu; Yan Qiao; Qing-Chang Xia
Journal:  Libyan J Med       Date:  2019-12       Impact factor: 1.657

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.